4/5/2023 7:22:47 AM
Eagle Pharma Reaches Settlement Agreement With Dr. Reddy's Laboratories Related To BENDEKA
3/13/2023 6:57:09 AM
Eagle Pharma Q4 Net Income $8.2 Mln Or $0.62/Shr Vs Loss Of $6.2 Mln Or $0.48/Shr Last Year
10/3/2022 8:33:04 AM
Eagle Pharma, Enalare Therapeutics Announce FDA Orphan Drug Designation For ENA-001 For Apnea Of Prematurity
3/28/2022 2:43:52 AM
Acacia Pharma, Eagle Pharma Agree Offer Terms
2/1/2022 6:57:13 AM
Eagle Pharma Announces Commercial Availability Of PEMFEXY On Nonsquamous Non-small Cell Lung Cancer
1/31/2022 6:53:48 AM
Eagle Pharma Says On Track To Support Submission Of Landiolol NDA In Q2 2022
1/18/2022 6:54:46 AM
Eagle Pharma Announces Commercial Availability Of Vasopressin, A-rated Generic Alternative To Vasostrict
12/20/2021 12:15:41 PM
Eagle Pharmaceuticals Reports That Par Has Unilaterally Withdrawn Attempt To Halt Launch Of Vasopressin
11/9/2021 7:07:41 AM
Eagle Pharmaceuticals Q3 Loss/sjhr $0.43 Vs. EPS $0.51 Last Year
8/31/2021 11:51:08 AM
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
8/31/2021 6:56:16 AM
Eagle Pharma Says U.S. Patent And Trademark Office Grants Additional Patent For Bendamustine Franchise
8/25/2021 6:56:36 AM
Eagle Pharma Announces Licensing Deal With Combioxin For Phase 2b/3Development Of CAL02 With Antibiotics
8/9/2021 6:57:32 AM
Eagle Pharma Q2 Net Income $3.6 Mln Or $0.27/Shr Vs Loss Of $0.3 Mln Or $0.02/shr Last Year